Institution: BeiGene has the potential to achieve sustainable revenue growth, the stock is rated as a buy.

Analysts Carol Dou and Sunny Chen from Dahua Jixian reported that BeiGene could achieve sustainable revenue growth by launching new products. They believe that the company's new revenue target of 5.1-5.3 billion US dollars is highly likely to be achieved, and they expect to further improve operational efficiency and cash generation through its global operating platform. Analysts from Dahua Jixian stated that BeiGene's cancer therapy Brukinsa may continue to boost global sales in the coming years, due to its best-in-class characteristics and expanding market penetration. They stated, "BeiGene has entered a new era of development and is expected to achieve positive profit and positive free cash flow from 2025 onwards." They attributed this to a more diversified revenue structure and continuously increasing profit margins. Dahua Jixian rates the stock as a buy, with a target price of 252.00 Hong Kong dollars.